What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?

Thuny, Franck; Bonaca, Marc P; Cautela, Jennifer

What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?

Thuny, Franck; Bonaca, Marc P; Cautela, Jennifer.

Afiliação

Thuny F; Aix-Marseille University, University Mediterranean Center of Cardio-Oncology, Department of Cardiology, Assistance Publique-Hôpitaux de Marseille, North Hospital, Marseille, France.
Bonaca MP; Center for CardioVascular and Nutrition Research (C2VN), Inserm 1263, Inrae 1260, Marseille, France.
Cautela J; French Working Group of Cardio-Oncology, France.

JACC CardioOncol ; 4(5): 624-628, 2022 Dec.

Article em En | MEDLINE | ID: mdl-36636431

Palavras-chave

2018-LL, 2018-Lake Louise; ACS, acute coronary syndrome; CMR, cardiac magnetic resonance; ECG, electrocardiogram; EMB, endomyocardial biopsy; IC-OS, International Cardio-Oncology Society; ICI, immune checkpoint inhibitor; ICI-M, immune checkpoint inhibitorinduced myocarditis; LGE, late gadolinium enhancement; MACE, major cardiovascular events; cTn, cardiac troponin; diagnosis; immunotherapy; irAE, immune-related adverse event; myocarditis; screening

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Revista: JACC CardioOncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google